NEW YORK, December 31, 2025, 13:38 ET — Regular session
- VNDA jumped after Vanda said the FDA approved Nereus to prevent motion-induced vomiting.
- Vanda said late-stage trials showed lower vomiting rates versus placebo, with a launch planned in coming months.
- Investors are watching pricing and rollout plans against entrenched over-the-counter rivals.
Vanda Pharmaceuticals shares jumped 28.1% to $9.01 at 1:38 p.m. ET on Wednesday after the company said the U.S. Food and Drug Administration approved Nereus (tradipitant) to prevent vomiting induced by motion. Vanda said the oral drug is a neurokinin-1 (NK-1) receptor antagonist — meaning it blocks a receptor involved in nausea signaling — and called it the first new pharmacologic motion-sickness treatment in more than four decades. In late-stage Phase 3 trials — the final stage before approval — vomiting rates were about 10%–20% on Nereus versus 38%–44% on placebo, and Vanda said it expects to launch the drug in coming months.
The clearance gives Vanda a rare, binary catalyst that can reshape a small drugmaker’s near-term outlook in a single session. Investors tend to reward biotechs that turn late-stage data into an FDA approval because it reduces scientific risk and shifts the debate to execution.
Motion-sickness treatment has long leaned on older medicines and patches, so a new entrant stands out. The commercial test, though, is straightforward: payers and patients must see enough value to choose a prescription product over inexpensive, familiar alternatives.
Motion sickness happens when the brain receives conflicting signals from the eyes and the inner ear during travel. The upside for Vanda is that vomiting prevention is a clear, measurable endpoint, which can help drive prescribing if real-world experience matches trial results.
The FDA’s decision follows a partial clinical hold — a regulatory pause — dating to 2018; the agency lifted it on Dec. 4 after reclassifying motion sickness as an acute condition, Reuters reported. “Sales of tradipitant solely in this indication could exceed $100 million annually at peak in the U.S. alone,” said H.C. Wainwright analyst Raghuram Selvaraju. Reuters said the approval was based on two late-stage studies involving 681 patients; the company did not comment on pricing, and existing options include Viatris’ Transderm Scop patch and the Bonine and Dramamine brands. Reuters
Those incumbents are widely available and low-cost, which sets a high bar for a new branded pill. Traders will be watching for concrete details on price, insurance coverage and how quickly Vanda can get product into pharmacies.
Launch execution will matter as much as the FDA headline. A slow rollout or a high out-of-pocket cost can limit early demand even when the clinical story is strong.
Investors will also look for signs that the trial results translate into routine travel use, not just controlled study settings. The next quarterly update should offer early clues on launch expenses and the pace of uptake.
Beyond the initial label, the market will focus on whether Vanda can expand tradipitant into other nausea-driven conditions. Broader labels typically require larger studies and more time, so timelines and trial design updates can move expectations quickly.
At Wednesday’s price, the market is effectively assigning value to a new revenue stream that was uncertain a week ago. That valuation can prove fragile if follow-through news on pricing and launch cadence is scarce.
The move is also a reminder that regulatory decisions can swamp broader market signals for small-cap biopharma names, particularly in year-end trading when liquidity can be thin. That environment can exaggerate gains as well as pullbacks.
